BLX 5000 / Biolexis Therap - LARVOL DELTA

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity (PRNewswire) - "Biolexis Therapeutics...today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity....The Metabolexis pipeline includes isoform-specific activators of AMPK, aGLP-1/GLP-1R agonists, and mTORC1 inhibitors with plans to file Investigational New Drug Applications (INDs) for all three agents by the end of Q4 2024 and to initiate First-In-Human Phase I safety clinical trials in Q1 2025."

IND • New P1 trial • Pipeline update • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus